Herbal medicine in the treatment of liver diseases

Digestive and Liver Disease

Volumn 39, Issue 4, 2007, Pages 293-304

  Stickel, F ^a   Schuppan, D ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alternative medicine; Antifibrotic therapy; Glycirrhizin; Hepatotoxicity; Herbal medicine; Liver disease; Silymarin

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ASTRAGALUS MEMBRANACEUS EXTRACT; ATRACTYLIS GUMMIFERA EXTRACT; AYURVEDIC DRUG; BU ZHONG YI QI TANG; CALLILEPIS LAUREOLA EXTRACT; CHELIDONIUM EXTRACT; GERMANDER EXTRACT; GLYCYRRHIZA GLABRA EXTRACT; GOMISIN A; HERBACEOUS AGENT; INTERFERON; KAMPO; KAVA EXTRACT; LARREA TRIDENTATA EXTRACT; NEOAMINOPHAGEN C; PHYLLANTHUS AMARUS EXTRACT; PLACEBO; PLANT EXTRACT; PLANTAGO ASIATICA EXTRACT; PYRROLIZIDINE ALKALOID; SALVIA MILTIORRHIZA EXTRACT; SENNA EXTRACT; SHI QUAN DA BU TANG; SILIBININ; SILYBUM MARIANUM EXTRACT; SILYMARIN; SPATOLOBUS SUBERECTUS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIAO CHAI HU TANG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ALCOHOL LIVER CIRRHOSIS; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ASCITES; ATRACTYLIS GUMMIFERA; AUTONOMIC NEUROPATHY; CALLILEPIS LAUREOLA; CHELIDONIUM; CHINA; CHOLESTATIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOG; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GERMANDER; HEADACHE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS; HEPATORENAL SYNDROME; HERBAL MEDICINE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; JAPAN; KIDNEY TUBULE NECROSIS; LARREA; LARREA TRIDENTATA; LICENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER VENOOCCLUSIVE DISEASE; METHODOLOGY; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PLANTAGO; PLANTAGO ASIATICA; POTASSIUM BLOOD LEVEL; RECOMMENDED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; SODIUM RETENTION; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANGIOSPERMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; GLYCYRRHIZIC ACID; HUMANS; LIVER DISEASES; MEDICINE, CHINESE TRADITIONAL; MEDICINE, KAMPO; PHYTOTHERAPY; PYRROLIZIDINE ALKALOIDS; SILYMARIN;

EID: 33947282103     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.11.004     Document Type: Short Survey

References (134)

1. Kim W.R., Brown R.S., Terrault N.A., and El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 36 (2002) 227-242
2. De Smet P.A.G.M. Herbal remedies. N Engl J Med 347 (2002) 2046-2056
3. Kessler R.C., Davis R.B., Foster D.F., Van Rompay M.I., Walters E.E., Wilkey S.A., et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135 (2001) 262-268
4. Strader D.B., Bacon B.R., Lindsay K.L., La Breque D.R., Morgan T., Wright E.C., et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 97 (2002) 2391-2397
5. Flora K.D., Rosen H.R., and Brenner K.G. The use of neuropathic remedies for chronic liver disease. Am J Gastroenterol 91 (1996) 2654-2655
6. Breevort P. The U.S. botanical market-an overview. Herbalogramm 36 (1996) 49-57
7. Wagner H., Seligmann O., Seitz M., Abraham D., and Sonnenbichler J. Silydianin und Silychristin, zwei isomere Silymarine aus Silybum marianum (Mariendistel). Z Naturforsch 31 (1976) 876-884
8. Floersheim G.L., Eberhard M., Tschumi P., and Duckert F. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol Appl Pharamcol 46 (1978) 455-462
9. Kroncke K.D., Fricker G., Meier P.J., Gerok W., Wieland T., and Kurz G. Alpha-amanitin uptake into hepatocytes. J Biol Chem 261 (1986) 12562-12567
10. Vogel G., Tuchweber B., Trost W., and Mengs U. Protection by silybinin against amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 73 (1984) 355-362
11. Floersheim G.L. Treatment of human amatoxin poisoning: myths and advances in therapy. Med Toxicol Advers Drug Exp 2 (1987) 1-9
12. Dehmlow C., Erhard J., and de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 (1996) 749-754
13. Fuchs E.C., Wehenmeyer R., and Weiner O.H. Effects of silibinin and of a synthetic analogue on a isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 12 (1997) 1383-1387
14. 4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 3 (1989) 183-191
15. Hall P., Plummer J.L., Ilsley A.H., Ahern M.J., Cmielewski P.L., and Williams R.A. The pathology of liver injury induced by the chronic administration of alcohol and low dose carbon tetrachloride in Porton rats. J Gastroenterol Hepatol 9 (1994) 250-256
16. Boigk G., Stroedter L., Herbst H., Waldschmitdt J., Ricken E.O., and Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1997) 643-649
17. Boigk G., Herbst H., Jia J.D., Riecken E.O., and Schuppan D. Effect of antifibrotic agent silymarin on liver cell regeneration in a rat model of secondary bilary fibrosis: a morphometric analysis. J Phytother Res 12 suppl. (1998) S42-S44
18. Jia J.D., Boigk G., Bauer M., Ruehl M., Strefeld T., Riecken E.O., et al. Silymarin downregulates TIMP-1 and collagen I mRNA in rats with secondary biliary cirrhosis. Hepatology 28 suppl. (1998) 546A
19. Ferenci P., Dragosic B., Dittrich H., Frank H., Benda L., Lochs H., et al. Randomized controlled clinical trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9 (1989) 105-113
20. Pares A., Planas R., Torres M., Caballerai J., Viver J.M., Acero D., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28 (1998) 615-621
21. Jacobs B., Dennehy C., Ramirez G., Sapp J., and Lawrence V.A. Milk thistle for the treatment of liver diseases: a systematic review and meta-analysis. Am J Med 113 (2002) 506-515
22. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
23. Magliulo E., Gagliardi B., and Fiori G.P. Zur Wirkung von Silymarin bei der Behandlung der akuten Virushepatitis. Med Klin 73 (1978) 1060-1065
24. Fintelmann V., and Albert A. Double blind trial of silymarin sodium in toxic liver damage. Therapiewoche 30 (1980) 5589-5594
25. Salmi H.A., and Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 17 (1982) 517-521
26. Tanasescu C., Petrea S., Baldescu R., Macarie E., Chiriloiu C., and Purice S. Use of the Romanian product Silimarina in the treatment of chronic liver diseases. Med Intern 26 (1988) 311-322
27. Trinchet J.C., Coste T., Levy V.G., Vivet F., Duchatelle V., Legendre C., et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol 13 (1989) 120-124
28. Bunout D., Hirsch S., Petermann M., de la Maza M.P., Silva G., Kelly M., et al. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chil 120 (1992) 1370-1375
29. Buzzelli G., Moscarella S., Giusti A., Duchini A., Marena C., and Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31 (1993) 456-460
30. Angulo P., Patel T., Jorgensen R.A., Therneau T.M., and Lindor K.D. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32 (2000) 897-900
31. Schuppan E.G., and Hahn E.G. Clinical studies with silymarin: fibrosis progression is the end point. Hepatology 33 (2001) 483-484
32. Yamamura Y., Kotaki H., Tanaka N., Aikawa T., Sawada Y., and Iga T. The pharmacokinetics of glycyrrhizin and its restaurative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats. Biopharm Drug Dispos 18 (1997) 717-725
33. Takahara T., Watanabe A., and Shiraki K. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J Hepatol 21 (1994) 601-609
34. Van Rossum T.G., Vulto A.G., De Man R.A., Brouwer J.T., and Schalm S.W. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12 (1998) 199-205
35. Wang J.Y., Guo J.S., Li H., Liu S.L., and Zern M.A. Inhibitory effect of glycyrrhizin on NF-kappa B binding activity in CCL4-plus ethanol-induced liver cirrhosis in rats. Liver 18 (1998) 180-185
36. Shiki Y., Shirai K., Saito Y., Yoshida S., Mori Y., and Wakashin M. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol 7 (1992) 12-16
37. Hayashi J., Kajiyama W., Noguchi A., Nahashima K., Hirata M., Hayashi S., et al. Glycyrrhizin withdrawal followed by human lymphoblasoid interferon in the treatment of chronic hepatitis B. Gastroenterol Jpn 26 (1991) 742-746
38. Abe Y., Ueda T., Kato T., and Kohli Y. Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 52 (1994) 1817-1822
39. Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., Koida I., et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79 (1997) 1494-1500
40. Thompson Coon J., and Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 40 (2004) 491-500
41. Fujiyama S., Chikazawa H., Honda Y., Kukida T., Iida S., Kawakami T., et al. Treatment of chronic active hepatitis C with interferon alpha 2b alone and in combination with Stronger Neo Minophagen C. Biother Jpn 12 (1998) 1495-1513
42. Suzuki Y., Ikeda K., Saitoh S., Kobayashi M., Tsubota A., Koida I., et al. A prospective randomised administration of Atronge Neo Minophagen C as an adjuvant therapy for chronic hepatitis type C treated with interferon. Acta Hepatol Jpn 37 (1996) 363-367
43. Van Rossum T.G.J., Vulto A.G., Hop W.C., Brouwer J.T., Niesters H.G., and Schalm S.W. Intraveouns glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomised, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14 (1999) 1093-1099
44. Tsubota A., Kumada H., Arase Y., Chayama K., Saitoh S., Ikeda K., et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol 11 (1999) 1077-1083
45. Van Rossum T.G.J., Vulto A.G., Hop W.C., Brouwer J.T., and Schalm S.W. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 96 (2001) 2432-2437
46. Zhang L., Cui Z., and Wang B. Therapeutic effects of stronger Neo-Minophagen C (SNMC) in patients with chronic liver disease. Hepatol Res 16 (2000) 145-154
47. Tandon A., Tandon B.N., and Bhujwala R.A. Treatment of subacute hepatitis with lamivudine and intravenous glycyrrhizin: a pilot study. Hepatol Res 20 (2001) 1-8
48. Zhang L., and Wang B. Randomized clinical trial with two doses (100 and 40 ml) of stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res 24 (2002) 220-227
49. Acharya S.K., Dasarathy S., Tandon A., Yoshi Y.K., and Tandon B.N. A preliminary open trial on interferon stimulator (SNMC) derived from glycyrrhiza glabra in the treatment of subacute hepatic failure. Ind J Med Res 98 (1993) 69-74
50. Kageyama Y., Suzuki H., and Saruta T. Renin-dependency of glycyrrhizin-induced pseudohyperaldosteronism. Endocrinol Jpn 38 (1991) 103-108
51. Calixto J.B., Santos A.R.S., Filbo V.C., and Yunes R.A. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 18 (1998) 225-258
52. Venateswaran P.S., Millman I., and Blumberg B.S. Effects of an extract from Phyllanthus niruri on hepatitis B virus and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA 84 (1987) 274-278
53. Chang C.W., Lin M.T., Lee S.S., Liu K.C., Hsu F.L., and Lin J.Y. Differential inhibition of reverse transcriptase and cellular DNA polymerase-alpha activities by lignans isolated from Chinese herbs, Phyllanthus myrtifolius Moon, and tannins from Lonicera japonica Thumb and Castanopsis hystrix. Antiviral Res 27 (1995) 367-374
54. Lee C.D., Ott M., Thyagarajan S.P., Shafritz D.A., Burk R.D., and Gupta S. Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. Eur J Clin Invest 26 (1996) 1069-1076
55. Ott M., Thyagarajan S.P., and Gupta S. Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest 27 (1997) 908-915
56. Liu J., Lin H., and McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hep 8 (2001) 368-466
57. Thyagarajan S.P., Subramanian S., Thirunalasundari T., Venkateswaran P.S., and Blumberg B.S. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 2 (1988) 764-766
58. Berk L., de Man R.A., Schalm S.W., Labadie R.P., and Heijtink R.A. Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed (letter). J Hepatol 12 (1991) 405-406
59. Leelarasamee A., Trakulsomboon S., Maunwongyathi P., Somanabandhu A., Pidetcha P., Matrakool B., et al. Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers. Lancet 335 (1990) 1600-1601
60. Milne A., Hopkirk N., Lucas C.R., Waldon J., and Foo Y. Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. NZ Med J 107 (1994) 243
61. Thamlikitkul V., Wasuwat S., and Kanchanapee P. Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. J Med Assoc Thai 74 (1991) 381-385
62. Thyagarajan S.P., Jayaram S., Valliamai T., Madanagopalan N., Pal V.G., and Jayaraman K. Phyllanthus amarus and hepatitis B. Lancet 336 (1990) 949-950
63. Schmidt K., Pittler M.H., and Ernst E. Bias in alternative medicine is still rife but is diminishing. Br Med J 323 (2001) 1071
64. Vickers A., Goyal N., Harland R., and Rees R. Do certain countries produce only positive results? A systematic review of controlled trails. Control Clin Trials 19 (1998) 159-166
65. Kayano K., Sakaida I., Uchida K., and Okita K. Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen expressions in cultured rat hepatic cells. J Hepatol 29 (1998) 642-649
66. Inoue T., and Jackson E.K. Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells. Eur J Pharmacol 378 (1999) 129-135
67. Sakaida I., Matsumura Y., Akiyama S., Hayashi K., Ishige A., and Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 28 (1998) 298-306
68. Ono M., Miyamura M., Kyotani S., Saibara T., Ohnishi S., and Nishioka Y. Effects of Sho-saiko-to extract on liver fibrosis in relation to the changes in hydroxyproline and retinoid levels of the liver in rats. J Pharm Pharmacol 51 (1999) 1079-1084
69. Shimizu I., Ma Y.R., Mizobuchi Y., Liu F., Miura T., Nakai Y., et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29 (1999) 149-160
70. Oka H., Yamamoto S., Kuroki T., Harihara S., Marumo T., Kim S.R., et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76 (1995) 743-749
71. Shiota G., Maeta Y., Mukoyama T., Yanagidani A., Udagawa A., Oyama K., et al. Effects of Sho saiko-to in hepatocarcinogenesis and 8-hydroxy-2′-deoxyguanosine formation. Hepatology 35 (2002) 1125-1133
72. Li T., Tamada K., Abe K., Tada H., Onoe Y., Tatsugami K., et al. The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Immunopharmacology 43 (1999) 11-21
73. Cyong J.C., Ki S.M., Iijima K., Kobayashi T., and Furuyi M. Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chin Med 28 (2000) 351-360
74. Chen T.S.N., and Chen P.S. Liver in traditional Chinese medicine. J Gastroenterol Hepatol 13 (1998) 437-442
75. Chang I.M. Liver-protective activities of aucubin derived from traditional oriental medicine. Res Commun Mol Pathol Pharmacol 102 (1998) 189-204
76. Chang IM. Antiviral activities of aucubin derived from traditional Chinese herbs in HepG2, woodchucks and humans infected with hepatitis B. Complementary and Alternative Medicine in Chronic Liver Disease. Submitted abstract, p65, 1999.
77. Jia J.D., Wang B.E., Dong Z., Cui L., Zhu J.X., and Che J.T. The effect of herbal compound 861 on mRNA levels for type I, III, and IV collagens and TGF in immune complex rat liver fibrosis. Chin J Hepatol 4 (1996) 214-216
78. Jia J.D., Wang B.E., and Ma X.M. The effect of herbal cpd 861 on type IV collagen mRNA levels in cultured rat lipocytes. Chin J Hepatol 4 (1996) 142-144
79. Wang H.J., and Wang B.E. Long-term follow-up result of compound Dan Shen granule (861 Chong Fu Ji) in treating hepatofibrosis. Chin J Integr Trad West Med 5 (1995) 4-5
80. Wang T.L., Wang B.E., Zhang H.H., Liu X., Duan Z.P., Zhang J., et al. Pathological study of the therapeutic effect on HBV-related liver fibrosis with herbal compound 861. Chin J Gastroenterol Hepatol 7 (1998) 148-153
81. Baoen W. Experimental and clinical study in inhibition and reversal of liver fibrosis with integrated Chinese and Western medicine. Complementary and alternative Medicine in Chronic Liver Disease, submitted abstract, p63, 1999.
82. Batey R.G., Bensousson A., Fan Y.Y., Bollipo S., and Hossain M. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatzol 13 (1998) 244-247
83. Pandey S., Gujrati V.R., Shanker K., Singh N., and Dhawan K.N. Hepatoprotective effect of LIV.52 against CCl4-induced lipid peroxidation in liver of rats. Int J Exp Biol 32 (1994) 694-697
84. de Silva H.A., Saparamadu P.A.M., Thabrew M.I., Pathmeswaran A., Fonseka M.M.D., and de Silva H.J. Liv 52 in alcoholic liver disease: a prospective, controlled trial. J Ethnopharmacol 84 (2003) 47-50
85. Huseini H.F., Alavian S.M., Heshmat R., Heydari M.R., and Abolmaali K. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine 12 (2005) 619-624
86. Chauhan B.L., and Kulkarni R.D. Effect of LIV.52, a herbal preparation, on absorbtion and metabolism of ethanol in humans. Eur J Clin Pharmacol 40 (1991) 189-191
87. Fleig W.W., Morgan M.Y., and Hölzer M.A. and a European multicenter study group. The ayurvedic drug LIV. 52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, palcebo-controlled clinical trial (abstract). J Hepatol 26 suppl. 1 (1997) 127
88. Kawada N., Seki S., Inoue M., and Kuroki T. Effect of antioxidants, resveratrol, quercetin, an N-acetylcysteine, on the functions of cultured hepatic stellate cells and Kupffer cells. Hepatology 27 (1998) 1265-1274
89. Godichaud S., Krisa S., Couronne B., Dubuisson L., Merillon J.M., Desmouiliere A., et al. Deactivation of cultured human liver myofibroblasts by trans-reseveratrol, a grapevine-derived polyphenol. Hepatology 31 (2000) 922-931
90. Stickel F., Patsenker E., and Schuppan D. Herbal hepatotoxicity. J Hepatol 43 (2005) 901-910
91. Woolf G.M., Petrovic L.M., Roiter S.E., Wainwright S., Villamil F.G., Katkov W.N., et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 10 (1994) 729-735
92. Picciotto A., Campo N., Brizzolara R., Giusto R., Guido G., Sinelli N., et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol 28 (1998) 165-167
93. Nadir A., Agrawal S., King P.D., and Marshall J.B. Acute hepatitis associated with the use of a Chinese herbal product, Ma-Huang. Am J Gastroenterol 91 (1996) 1436-1438
94. Skoulidis F., Alexander G.J.M., and Davies S.E. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol 17 (2005) 581-584
95. Bajaj J., Knox J.F., Komorowski R., and Saeian K. The irony of herbal hepatitis: Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig Dis Sci 48 (2003) 1925-1928
96. Davies E.G., Pollock I., and Steel H.M. Chinese herbs for eczema. Lancet 336 (1990) 38
97. Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet 346 (1992) 674
98. Perharic-Walton L., and Murray V. Toxicity of traditional Chinese herbal remedies. Lancet 346 (1992) 674
99. Kane J.A., Kane S.P., and Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 36 (1995) 146-147
100. Yoshida E.M., McLean C.A., Cheng E.S., Blanc P.D., Somberg K.A., Ferrell L.D., et al. Chinese herbal medicine, fulminant hepatitis and liver transplantation. Am J Gastroenterol 12 (1996) 2647-2648
101. Wilmot F.C., and Robertson G.W. Senecio disease or cirrhosis of the liver due to senecio poisoning. Lancet II (1920) 828-829
102. Bras G., Jeliffe D.B., and Stuart K.L. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 57 (1954) 285
103. Tandon B.N., Tandon R.K., Tandon H.D., Narndranathan M., and Joshi Y.K. An epidemic of veno-occlusive disease of liver in Central India. Lancet 2 (1976) 271-272
104. Datta D.V., Khuroo M.S., Mattocks A.R., Aikat B.K., and Chhuttani P.N. Herbal medicine and veno-occlusive disease in India. Postgrad Med J 54 (1978) 511-515
105. Stillman A.E., Huxtable R.J., Consroe P., Kohnen P., and Smith S. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroentrology 73 (1977) 349-352
106. Fox D.W., Hart M.C., Bergeson P.S., Jarrett P.B., Stillman A.E., and Huxtable R.J. Pyrrolizidine (Senecio) intoxication mimicking Reye's syndrome. J Pediatr 93 (1978) 980-982
107. Weston C.F.M., Cooper B.T., Davies J.D., and Levine D.F. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J 295 (1987) 183
108. Roulet M., Laurini R., Rivier L., and Calame A. Hepatic veno-occlusive disease in a newborn infant of a woman drinking herbal tea. J Pediatr 112 (1988) 433-436
109. DeLeve L.D., Shulman H.M., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-42
110. Diaz D., Ferroudji S., and Heran B. Hépatite aigue à la Germandrée petit-chene. Gastroenterol Clin Biol 16 (1993) 1006-1007
111. Larrey D., Vial T., Pauwels A., Castot A., Biour M., David M., et al. Hepatitis after Germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Int Med 117 (1992) 129-132
112. Mostefa-Kara N., Pauwels A., Pines E., Biour C., and Levy V.G. Fatal hepatitis after herbal tea. Lancet 340 (1992) 674
113. Larrey D., and Pageaux G.P. Hepatotoxicity of herbal remedies and mushrooms. Semin Liver Dis 15 (1995) 183-188
114. Fau D., Lekehal M., Farrell G., Moreau A., Moulis C., Feldmann G., et al. Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 113 (1997) 1334-1346
115. Mattei A., Rucay P., and Samuel D. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol 22 (1995) 597
116. Colombo M.L., and Bosisio E. Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol Res 33 (1996) 127-134
117. Strahl S., Ehret V., Dahm H.H., and Maier K.P. Necrotizing hepatitis after taking herbal medication extracts of kava or of common or lesser celandine (article in German). Dtsch Med Wochenschr 123 (1998) 1410-1414
118. Greving I., Meister V., Monnerjahn C., Müller K.M., and May B. Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmaepidemiol Drug Saf 7 (1998) S66-S69
119. Benninger J., Schneider H.T., Schuppan D., Kirchner T., and Hahn E.G. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 117 (1999) 1234-1237
120. Stickel F., Seitz H.K., Hahn E.G., and Schuppan D. Acute hepatitis induced by greater celandine. Scand J Gastroenterol 38 (2003) 565-568
121. Pittler M.H., and Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20 (2000) 84-89
122. Stickel F., Baumüller H.M., Seitz K.H., Vasilakis D., Seitz G., Seitz H.K., et al. Hepatitis induced by Kava-Kava (Piper methysticum rhizoma). J Hepatol 39 (2003) 62-67
123. Russmann S., Lauterburg B.H., and Helbling A. Kava hepatotoxicity. Ann Intern Med 135 (2001) 68-69
124. Kassler W.J., Blanc P., and Greenblatt R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med (1991) 2281-2288
125. Sheikh N.M., Philen R.M., and Love L.A. Chaparral-associated Hepatotoxicity. Arch Intern Med 157 (1997) 913-919
126. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 26 (1997) 47-54
127. Stewart M.J., and Steenkamp V. The biochemistry and toxicity of atractyloside: a review. Ther Drug Monit 22 (2000) 641-649
128. Beuers U., Spengler U., and Pape G. Hepatitis after chronic abuse of senna. Lancet 337 (1991) 372-373
129. Thomassen D., Slattery J.T., and Nelson S.D. Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. J Pharmacol Exp Ther 253 (1990) 567-572
130. Anderson I.B., Mullen W.H., Meeker J.E., Khojasteh-Bakht S.C., Oishi S., Nelson S.D., et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 124 (1996) 726-734
131. Bonkovsky H.L. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 144 (2006) 68-71
132. Hamid S., Rojter S., and Vierling J. Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med 127 (1997) 169
133. Millonig G., Stadlmann S., and Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol 17 (2005) 445-447
134. Lynch C.R., Folkers M.E., and Hutson W.R. Fulminant hepatic failure associated with the use of Black Cohosh: a case report. Liver Transpl 12 (2006) 989-992